Anti-Amyloid Treatment of Asymptomatic Alzheimer's A4
Posted Jul 18 2012 1:42pm
Although evidence suggests that amyloid deposits (or "plaques") in the brain are associated with an increased risk of cognitive decline, the impact of being "amyloid positive" on the likelihood and timing of progressing to Alzheimer's dementia on an individual basis remains unknown.
Alzheimer's Reading Room
The beginning of secondary prevention trials in people with presymptomatic Alzheimer's provides an important research opportunity to evaluate the impact of learning one's amyloid status.
One such trial is the Anti-Amyloid treatment of Asymptomatic Alzheimer's disease (A4) trial being proposed by the Alzheimer's Disease Cooperative Study.
PET amyloid imaging and/or cerebrospinal fluid markers of beta amyloid accumulation will be used to select participants for the trial, which will test an experimental treatment in older adults who are cognitively normal and amyloid-positive for three years.
The goal is to test the hypothesis that decreasing "upstream" amyloid accumulation will slow "downstream" brain cell death and cognitive decline.
The video is informative and well worth watching. Should be shared in the Alzheimer's community.
Original content Bob DeMarco, the Alzheimer's Reading Room